What is Ishita Drugs & Industries Ltd (524400) share price return in the past 10 years?

Ishita Drugs & Industries Ltd share price has appreciated 18.7% annually (CAGR) over the past ten years.

What is the share price of Ishita Drugs & Industries Ltd (524400)?

Company share prices are keep on changing according to the market conditions. The current trading price of Ishita Drugs & Industries Ltd (524400) on 04-Jun-2026 16:59:59 at 16:59 is 77.70.

What is the P/E ratio of Ishita Drugs & Industries?

The latest standalone P/E ratio of Ishita Drugs & Industries as of 04-Jun-2026 is 29.90.

What is the P/B ratio of Ishita Drugs & Industries Ltd (524400)?

The latest standalone P/B ratio of Ishita Drugs & Industries Ltd (524400) as of 04-Jun-2026 is 2.01.

What is the 52-week high and low of Ishita Drugs & Industries Ltd (524400)?

The 52-week high of Ishita Drugs & Industries Ltd (524400) is Rs. 90.85 and the 52-week low is Rs. 66.00.

Ishita Drugs & Industries Ltd (524400) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Ishita Drugs & Industries Ltd (524400)
Brand: Ishita Drugs & Industries

Key Metrics

Valuation Multiples

Market Cap

₹23 Cr.

Current Price

₹77.7

52-Week Low / High

₹66 / 91

TTM EPS

₹2.6

TTM Sales

₹14.7 Cr.

Book Value per Share

₹38.7

P/E Ratio

29.90

Higher than its 5-year historical median

Industry PE

46.5

Price to Book (P/B)

2.01

In line with its 5-year historical median

Price to Sales (P/S)

1.58

Higher than its 5-year historical median

EV/EBITDA

16.65

Higher than its 5-year historical median

Dividend Yield

0.00%

Profitability Efficiency

Return on Equity (ROE)

8.38%

Underperforms industry median

Return on Capital Employed (ROCE)

9.97%

Underperforms industry median

Return on Assets (ROA)

6.41%

Operating Profit Margin

6.7%

Net Profit Margin

5.79%

Gross Profit Margin

8.4%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-1.25%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

9.89%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

16%

Asset Quality

Promoter Holding

50.04%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹9 Cr.

Equity

₹3 Cr.

Face Value

₹10

All Time Low / High

₹0.10 / 104.75

Ishita Drugs & Industries stock performance

Key Ratios

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Ishita Drugs & Industries Ltd a good quality company?

Ishita Drugs & Industries Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Ishita Drugs & Industries Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Ishita Drugs & Industries Ltd vs industry peers?

Ishita Drugs & Industries Ltd revenue CAGR is 0.23%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Q.1 Promoter shareholding and pledge status of Ishita Drugs & Industries Ltd?

Promoters hold 50.04% of the Ishita Drugs & Industries Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Ishita Drugs & Industries Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 18.3% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	4%	4.8%	7.3%	8.2%	10.8%	14.4%	13%	8.9%	10.7%	10%	-
Value Creation Index ⓘ	-0.7	-0.7	-0.5	-0.4	-0.2	0.0	-0.1	-0.4	-0.2	-0.3	-
Growth Parameters ⓘ
Sales ⓘ	6.5	5.8	6.8	9.1	14.8	14	14.1	12.1	15.2	15	15
Sales YoY Gr.	-	-10.7%	15.9%	34.3%	63.2%	-5.9%	1%	-14.3%	25.9%	-1.3%	-
Adj EPS ⓘ	0.5	0.6	0.7	1	1.6	2.1	2.6	1.8	2.3	2.8	2.6
YoY Gr.	-	22%	6.6%	47.7%	62.5%	37.2%	21.5%	-30.8%	26.1%	22.5%	-
BVPS (₹) ⓘ	18.8	19.4	20.3	21.5	23.3	26.1	28.8	30.7	33.2	36.1	38.7
Adj Net Profit ⓘ	0.2	0.2	0.2	0.3	0.5	0.6	0.8	0.5	0.7	0.8	1
Cash Flow from Ops. ⓘ	0.3	0.5	0.7	0.8	1.1	-0.7	3.1	-2.9	2.1	-3.6	-
Debt/CF from Ops. ⓘ	4.3	0	0.2	0.3	0.3	-0.1	0	-0.3	0	-1.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	9.7%	0.2%	2.1%	-1.3%
Adj EPS ⓘ	21%	12.3%	2.3%	22.5%
BVPSⓘ	7.5%	9.2%	7.9%	8.7%
Share Price	18.7%	17.7%	14.6%	-3.6%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	2.7	3.2	3.3	4.6	7	8.7	9.5	6.1	7.1	8	7
Op. Profit Mgn % ⓘ	4.1	5.5	6.7	5.7	5.2	6.6	7.7	6.3	6	6.7	5.2
Net Profit Mgn % ⓘ	2.3	3.1	2.9	3.1	3.1	4.6	5.5	4.5	4.5	5.6	5.3
Debt to Equity ⓘ	0.2	0	0	0	0	0	0	0.1	0	0.4	0
Working Cap Days ⓘ	141	145	105	72	50	62	55	80	67	104	168
Cash Conv. Cycle ⓘ	64	56	49	27	3	11	3	25	45	79	136

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	6.54	5.84	6.77	9.09	14.83	13.95	14.09	12.07	15.19	15
Operating Expenses ⓘ +	6.29	5.55	6.32	8.57	14.07	13.03	13	11.31	14.28	14
Manufacturing Costs	0.27	0.42	0.41	0.68	0.77	0.72	0.63	0.53	0.55	0.79
Material Costs	5.02	3.95	4.71	6.37	11.41	10.23	10.14	8.51	11.22	10.54
Employee Cost	0.41	0.45	0.56	0.67	0.76	0.76	0.76	0.77	0.83	0.83
Other Costs ⓘ	0.59	0.73	0.64	0.86	1.12	1.32	1.47	1.50	1.69	1.83
Operating Profit ⓘ	0.25	0.29	0.45	0.52	0.76	0.92	1.09	0.76	0.91	1
Operating Profit Margin (%)	3.8%	4.9%	6.7%	5.7%	5.1%	6.6%	7.7%	6.3%	6.0%	6.7%
Other Income ⓘ +	0.15	0.15	0.12	0.16	0.16	0.31	0.11	0.20	0.28	0.34
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.06	0.04	0.11	0.06	0.03	0.03	0.02	0.05	0.09	0.07
Depreciation ⓘ	0.15	0.14	0.14	0.16	0.18	0.15	0.13	0.13	0.11	0.11
Profit Before Tax ⓘ	0.19	0.26	0.32	0.46	0.71	1.05	1.04	0.78	0.99	1.16
Tax ⓘ	0.06	0.07	0.08	0.11	0.17	0.22	0.24	0.20	0.24	0.29
Profit After Tax	0.14	0.18	0.25	0.35	0.55	0.83	0.80	0.58	0.75	0.87
PAT Margin (%)	2.1%	3.1%	3.7%	3.9%	3.7%	6.0%	5.7%	4.8%	4.9%	5.8%
Adjusted EPS (₹)	0.5	0.6	0.8	1.2	1.8	2.8	2.7	1.9	2.5	2.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Ishita Drugs & Inds. - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	5.63	5.81	6.06	6.41	6.96	7.79	8.60	9.17	9.92	10.79
Share Capital ⓘ	2.99	2.99	2.99	2.99	2.99	2.99	2.99	2.99	2.99	2.99
Reserves ⓘ	2.64	2.82	3.07	3.42	3.97	4.80	5.61	6.18	6.93	7.80
Debt +	1.11	0.01	0.09	0.13	0.21	0	0	0.96	0	3.90
Long Term Debt	0	0	0.08	0.12	0.04	0	0	0	0	0.09
Short Term Debt	1.11	0.01	0	0	0.17	0	0	0.96	0	3.81
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	1.26	1.18	0.56	1.38	1.89	0.98	2.04	0.86	0.46	0.95
Others Liabilities ⓘ	0.21	0.18	0.44	0.42	0.48	0.49	0.62	0.42	0.43	0.65
Total Liabilities ⓘ	8.20	7.19	7.15	8.34	9.55	9.26	11.25	11.41	10.81	16.30
Fixed Assets
Net Fixed Assets ⓘ +	1.11	1.02	1.19	1.30	1.14	1	0.88	0.89	0.80	0.88
Gross Block	4.11	4.16	4.46	4.73	4.75	4.75	4.60	4.73	4.76	4.84
Accumulated Depreciation	3	3.14	3.28	3.43	3.61	3.76	3.71	3.84	3.95	3.96
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	2.15	2.70	3.15	4.04	5.29	3.11	4.06	3.39	3.34	3.87
Inventories	0.77	0.56	0.72	0.74	0.58	0.65	0.97	1.60	1.06	4.46
Trade Receivables	1.88	1.70	0.82	1.18	1.31	1.52	0.54	1.80	0.70	1.90
Cash Equivalents ⓘ	2.19	1.11	1.20	1.01	1	2.54	4.68	3.43	4.81	4.83
Others Assets ⓘ	0.09	0.10	0.08	0.07	0.22	0.44	0.11	0.30	0.09	0.35
Total Assets ⓘ	8.20	7.19	7.15	8.34	9.55	9.26	11.25	11.41	10.81	16.30

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.26	0.52	0.72	0.79	1.05	-0.67	3.08	-2.90	2.12	-3.64
PBT ⓘ	0.19	0.26	0.32	0.46	0.71	1.05	1.04	0.78	0.99	1.16
Adjustment ⓘ	0.06	0.03	0.13	0.05	0.05	-0.14	0.05	-0.02	-0.08	-0.15
Changes in Working Capital ⓘ	0.08	0.32	0.35	0.39	0.46	-1.36	2.24	-3.45	1.45	-4.34
Tax Paid ⓘ	-0.07	-0.09	-0.08	-0.12	-0.18	-0.23	-0.25	-0.21	-0.24	-0.30
Cash Flow From Investing Activity ⓘ +	-0.28	-0.55	-0.69	-1.06	-1.15	2.45	-0.93	0.59	0.13	-0.67
Capex	-0.01	-0.04	-0.31	0	0	0	0	-0.13	-0.03	-0.18
Net Investments	-0.33	-0.51	-0.38	-1.06	-1.27	2.18	-0.97	0.67	0.06	-0.53
Others ⓘ	0.06	0	0	0	0.12	0.27	0.04	0.06	0.10	0.05
Cash Flow From Financing Activity ⓘ +	1.07	-1.05	0.05	0.09	0.09	-0.24	0	1.05	-0.87	4.33
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-0.06	-0.04	-0.11	-0.06	-0.03	-0.03	-0.02	-0.05	-0.09	-0.07
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	1.13	-1	0.16	0.15	0.13	-0.21	0.03	1.10	-0.78	4.40
Net Cash Flow ⓘ	1.05	-1.08	0.08	-0.19	-0.01	1.54	2.14	-1.25	1.38	0.02

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	2.47	3.19	4.17	5.64	8.18	11.25	9.82	6.5	7.84	8.38
ROCE (%)	4.02	4.79	7.26	8.17	10.79	14.39	13	8.9	10.74	9.97
Asset Turnover Ratio	0.94	0.84	0.96	1.17	1.66	1.48	1.37	1.07	1.37	1.11
PAT to CFO Conversion(x)	1.86	2.89	2.88	2.26	1.91	-0.81	3.85	-5	2.83	-4.18
Working Capital Days
Receivable Days	80.60	101.60	66.80	40.20	30.70	37.10	26.80	35.40	30	31.60
Inventory Days	53.30	37.60	33.90	29.30	16.20	16.20	21.10	38.90	32	67.30
Payable Days	86.30	112.80	67.50	55.60	52.30	51.30	54.40	62.10	21.40	24.40

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Ishita Drugs & Industries Ltd FAQs

The current trading price of Ishita Drugs & Inds. on 04-Jun-2026 16:59 is ₹77.70.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Ishita Drugs & Inds. stood at ₹23.23 Cr

The latest P/E ratio of Ishita Drugs & Inds. as of 03-Jun-2026 is 29.90.

The latest P/B ratio of Ishita Drugs & Inds. as of 03-Jun-2026 is 2.01.

The 52-week high of Ishita Drugs & Inds. is ₹90.85 and the 52-week low is ₹66.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ishita Drugs & Inds. is ₹14.66 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Ishita Drugs & Industries Ltd is a average quality company.

The key valuation ratios of Ishita Drugs & Industries Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Ishita Drugs & Industries Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Ishita Drugs & Industries Ltd

Ishita drugs & industries limited (IDIL), an Ishita Group company was incorporated in 1992, the company is listed on the local stock exchanges in India and has earned a reputation as a 'high quality manufacturer' in a very short time.

IDIL is engaged in the manufacture of various active pharma ingredients (bulk actives and their salts), bulk drug intermediates, excipients and fine chemicals. It has a state-of-art manufacturing facility, in terms of chemical synthesis, quality control and environmental safety.

Ishita Group is a respected member of the Indian business community for more than 3 decades. The group's interests encompass manufacture of a large number of bulk actives and their salts, drug intermediates, fine chemicals, food additives, specialty/ performance chemicals, pharmaceutical formulations, healthcare products, dyes and dye intermediates, distribution of financial products and other businesses. The ishita group derives its key strengths from its strong ethical practices and moral values in business commitments.

The companyâ€™s manufacturing facility is located on main State Highway 17, barely 25 km from Ahmedabad city. The plant incorporates facilities that are the state-of-art in chemical synthesis, quality control and energy efficiency. The provision of several different utility systems and equipments covering a large number of unit operations make the plant truly multi-purpose. This imparts the flexibility to alter the product mix in tune with the changing market needs or the needs of the customers for customized products.

The plant is equipped with various kinds of equipment to carry out varied kinds of reactions - ss vessels, glass lined ss reactors (glrs), ss centrifuges, rubber lined centrifuges, condensers, fluid bed dryers, ribbon blender, commuting mill, leaf filters, vibrator separators, multi mill etc. The plant also have various utilities suitable for different processes - oil heating, steam heating, ammonia chilling, brine chilling, compressed air, vacuum systems etc.

Product range of the company includes:

The current product list of Ishita includes APIs and intermediates

APIs

Antibiotics

Chloramphenicol bp/usp
Chloramphenicol palmitate bp/usp

Fluoro quinolones

Norfloxacin ip/usp/bp
Enrofloxacin base vet

Sulpha drugs

Sulfacetamide plain bp/usp
Sulphacetamide sodium (drc)
Sulfanilamide

Vitamins

Nicotinamide usp (inj.) / cosmetics grade
Nicotinic acid bp/usp

Anthelmintics

Piperazine hydrate
Piperazine citrate / adipate / phosphate

Iodides & citrates (salts)

Pot.iodide bp
Sod.iodide bp
Methyl iodide bp
Pot.citrate bp/usp
Sod.citrate bp/usp
Sod.acid citrate bp
Sodium chloride bp (pyrogen free)
Potassium chloride bp (pyrogen free)

Excipients

Maize starch bp
Sod.starch glycolate usp
Pumojel (sod.starch glycolate)

Other chemicals

Methyl nicotinate
Pyrazinamide
Salicylanilide
Para bromo toluene 99.5%
Pyridine hydrobromide
Potassium phthalimide
Nicotinic acid hydrazide

Intermediaries

4-sulfonamido phenyl hydrazine hcl (celecoxib intermediate)
4-chloro phenyl hydrazine hydrochloride
Q-acid and n2 ester (norfloxacin intermediates)
Tri methyl sulphonoxium iodide
5 cyano phthalide
7-amino - 3 phenyl coumarin
2-hydroxy methyl 3,5 dimethyl 4-methoxy pyridine (omeprazole int.)
Hexa methyl disilazane
5-chloromethopabate
Diacetyl sulfanilamide
L-alanine benzylester p-toluene sulfonate salt
4 (chloroacetyl) n-methyl sulfonamide
Indole - 2 - carboxylic acid
Ethyl benzoyl acrylate
4, 4' - dimethyl benzil

Ishita Drugs & Industries Ltd (524400)

Ishita Drugs & Industries Ltd (524400)

Ishita Drugs & Industries stock performance